The HHS and FDA are encouraging stakeholders to submit their ideas for deregulatory actions in the next 60 days.

Researchers found a significant tradeoff between harms and benefits for patients who received an ICI plus chemotherapy in the first-line setting.

Penpulimab-kcqx, a humanized immunoglobulin G1 monoclonal antibody, blocks the interaction between the programmed death 1 receptor on T-cells and programmed death ligand 1 and 2 on tumor cells.